Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data

Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026.

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.
Seeking Alpha

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data

Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...
Nasdaq

Positive Phase 1b Results for I-Mab's Givastomig in Metastatic Gastric Cancer Show 71% Objective Response Rate with Favorable Safety Profile

I-Mab reported positive Phase 1b study results for givastomig in metastatic gastric cancers, highlighting significant efficacy and a favorable safety profile. I-Mab has announced positive results from ...
Hosted on MSN

Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621

Kymera Therapeutics (NASDAQ:KYMR) Monday reported positive Phase 1 results from its healthy volunteer study of KT-621, a first-in-class oral STAT6 degrader, sending shares up +35% in premarket trading ...
Seeking Alpha

Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst

Celcuity (CELC) recently released positive results from its phase 3 VIKTORIA-1 trial, which used its drug gedatolisib in combination with other therapies to treat patients with PIK3CA wildtype ...